A Dual Stimuli‐Responsive Nanoplatform Loaded PtIV‐Triptolide Prodrug for Achieving Synergistic Therapy toward Breast Cancer

• DOI: 10.1002/adhm.202301328
• Publication Date: 2023-07-01T10:04:55Z
• Authors: Kang Fang; Yanting Sun; Jingxian Yang; Xiaochun Hu; Mengyao Chen; Ruihao Li; Xinda Yang; Ting Fan; Junjie Wu; Xiaohan Tong; Chunyan Dong; Shuo Shi
• Keywords: Triptolide; Cancer Therapy

Abstract To strengthen the antitumor efficacy and avoid toxicity to normal cells of cisplatin triptolide, herein, an acid glutathione (GSH) dual‐controlled nanoplatform for enhanced cancer treatment through synergy both “1+1” apoptosis ferroptosis is designed. Remarkably, ZIF8 in response tumor microenvironment enhances drug targeting protects drugs from premature degradation. Meanwhile, Pt IV center can be easily reduced because large amount GSH, thus liberating triptolide as coordinated ligand. The released hemin turn boost cell chemotherapy photodynamic therapy, respectively. Furthermore, GSH reduction weakens activation peroxidase 4 (GPX4) effectively. inhibit expressions by regulating nuclear factor E2 related 2 (Nrf2), further promoting membrane lipid peroxidation, achieved. Both vitro vivo results demonstrate that nanosystem not only perform superior specificity therapeutic outcomes but also reduce cells/tissues Overall, prodrug‐based smart system provides efficient strategy virtue effect therapies.